<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000119312523068397/d408324d8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000119312523068397/0001193125-23-068397-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Aeglea BioTherapeutics Inc

Announcement: AGLE 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000095017023005705/agle-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000095017023005705/0000950170-23-005705-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Aeglea Reports Positive Results for Pegzilarginase##:
Aeglea announces promising results from pegzilarginase trials for Arginase 1 Deficiency. Future prospects discussed.

Current Analysis##:
Aeglea has reported encouraging results for its pegzilarginase Phase 3 trials for Arginase 1 Deficiency.
The drug appears to have successfully reduced plasma arginine and metabolite levels, leading to a detectable clinical benefit for patients.
The submission of a Biologics License Application was met with FDA concerns around supporting data, but dialogue is ongoing.

Forward-Looking Analysis##:
Aeglea's pegtarviliase and pegzilarginase programs show promise for benefitting people with rare metabolic diseases.
The focus is on advancing pegtarviliase toward commercialization with the potential to address a global market of 30,000 patients for Classical Homocystinuria.
Aeglea has more innovative potential treatments for Cystinuria and other diseases. However, the company reported a net loss of $83.8 million in 2022, and moving forward, the firm needs to continue to seek financing to continue progress.

Announcement: AGLE 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000095017023005699/agle-20230302.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000095017023005699/0000950170-23-005699-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 7.01 Item 9.01

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1472322/000110465923021874/tm236168d16_sc13ga.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000110465923021874/0001104659-23-021874-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: AGLE SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1055951/000094787123000163/ss1758550_sc13ga.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000094787123000163/0000947871-23-000163-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000119312523036871/d422280dsc13ga.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1636282/000119312523036871/0001193125-23-036871-index.htm>Original filing index</a>
                    </div>